<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261102071643N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-07</date_registration>
      <primary_sponsor>Sheikh Zayed Hospital</primary_sponsor>
      <public_title>C reactive protein point of care testing for safely reducing the use of antibiotics for acute exacerbation of COPD</public_title>
      <acronym></acronym>
      <scientific_title>C reactive protein point of care testing for safely reducing the use of antibiotics for acute exacerbation of COPD</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-02-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>164</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/94590</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible patients will be randomized individually in a 1:1 ratio into two parallel groups: the CRP point-of-care testing-guided group (Group A) and the usual-care group (Group B). Simple randomization will be performed using a computer-generated random sequence prepared through statistical software. Each participant will be assigned a unique study identification number, and the random allocation sequence will determine the treatment group.
Allocation concealment will be ensured using sequentially numbered, opaque, sealed envelopes (SNOSE), prepared according to the computer-generated randomization sequence by an independent person not involved in patient recruitment or treatment allocation. After confirming eligibility and obtaining written informed consent, the investigator will open the next sequentially numbered envelope to determine the participant's group assignment.
No stratification will be performed. The study will be open-label; therefore, blinding of patients and treating physicians will not be feasible. However, allocation concealment will be maintained until the participant has been enrolled and assigned to a group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: CRP-guided antibiotic prescribing. Patients will undergo CRP point-of-care testing, and antibiotic prescribing will be guided by CRP levels ≥20 mg/L in conjunction with clinical assessment by a consultant pulmonologist. Intervention 2: Control group: Usual care. Antibiotic prescribing will be based on clinical assessment and the judgment of the treating consultant pulmonologist without CRP point-of-care testing.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to patient confidentiality, data privacy concerns, and institutional ethical requirements, deidentified individual participant data will not be made publicly available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Muhammad Waqas Jamil</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hospital Road</address>
        <city>Rahim Yar Khan</city>
        <country1>Pakistan</country1>
        <zip>64200</zip>
        <telephone>+92 331 3304141</telephone>
        <email>jamilwaqas4@gmail.com</email>
        <affiliation>Sheikh Zayed Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Muhammad Waqas Jamil</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hospital Road</address>
        <city>Rahim Yar Khan</city>
        <country1>Pakistan</country1>
        <zip>64200</zip>
        <telephone>+92 331 3304141</telephone>
        <email>jamilwaqas4@gmail.com</email>
        <affiliation>Sheikh Zayed Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age of 40-60 years
Both genders
Clinically diagnosed cases of AECOPD as per operational definition</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant women.
Patients who had received antibiotics within the past 5 days.
Those involved in other research studies or those who had recently participated in the trial.
Patients considered unable or unwilling to follow the protocol or provide consent.
Malignancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J44.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic obstructive pulmonary disease with (acute) exacerbation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: CRP-guided antibiotic prescribing. Patients will undergo CRP point-of-care testing, and antibiotic prescribing will be guided by CRP levels ≥20 mg/L in conjunction with clinical assessment by a consultant pulmonologist.</i_keyword>
      <i_keyword>Control group: Usual care. Antibiotic prescribing will be based on clinical assessment and the judgment of the treating consultant pulmonologist without CRP point-of-care testing.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Proportion of patients receiving antibiotics in the CRP-guided group compared with the usual-care group. Timepoint: Within four weeks of enrolment, assessed at initial consultation and follow-up visits at weeks 1, 2, and 4. Method of measurement: Measured as the number and percentage of patients receiving at least one antibiotic prescription during the four-week follow-up period, based on clinical records and patient follow-up interviews, and compared between the two groups.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Proportion of patients receiving antibiotics at the initial consultation in both study groups. Timepoint: At the initial consultation (baseline). Method of measurement: Recorded as the number and percentage of patients prescribed antibiotics at the initial consultation, based on prescription records.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sheikh Zayed Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-11</approval_date>
        <contact_name>ERB, Sheikh Zayed Hospital, Rahim Yar Khan</contact_name>
        <contact_address>Hospital Road Rahim Yar Khan Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
